Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Higher AML, MDS risk linked to autotransplants

Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Key clinical point: Autotransplant for lymphoma or plasma cell myeloma is a strong risk factor for AML and myelodysplastic syndrome.

Major finding: Patients undergoing autologous hematopoietic cell transplantation have risks for AML and MDS that are 10-100 times higher than those of the general population.

Study details: A retrospective cohort study of 9,028 patients undergoing hematopoietic cell autotransplant during 1995-2010 for Hodgkin lymphoma, non-Hodgkin lymphoma, or plasma cell myeloma.

Disclosures: The Center for International Blood and Marrow Transplant Research is supported by U.S. government agencies and numerous pharmaceutical companies. The authors reported that they have no relevant conflicts of interest.

Read the article.

Citation:

Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

This Week's Must Reads

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005

Adding mobile apheresis to community blood drives, Anthony D et al. AABB 2018, Poster BBC 135

Study assesses blood delivery errors, Vossoughi S et al. AABB 2018, Abstract QT4

CAR T-cell cost effectiveness in ALL, Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530

Must Reads in Aggressive Lymphomas

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Throly system predicts thromboprophylaxis in lymphoma patients, Leukemia and Lymphoma 2018, Dubrovnik, Croatia

First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10